News

Respiratory syncytial virus (RSV) is a viral infection that can prove fatal to young children and the elderly and for which no preventive treatment by vaccine is currently

The company submitted the new drug application (NDA) in May and the FDA gave priority review status to the application in June. The FDA has set a priority

The acquired assets of Discovery Partners International (DPI) have now become a part of Galapagos’ service division BioFocus DPI. “Galapagos acquired the operational activities of DPI as part

The study is being conducted with several hundred healthy adults in Austria and Singapore using the fully inactivated wild-type H5N1 strain A/Vietnam/1203/2004. Four different antigen concentrations ranging from

All required legal procedures with the relevant Chinese government regulatory and audit procedures have been completed and the title ownership of 100% of Enshi has been passed to

Actavis needs to gain approval from the Croatian financial authorities in order to proceed with its takeover bid. Actavis has submitted a proposal to pay Pliva shareholders a

Under the agreement, the companies will initiate two parallel programs. One of these will evaluate a combination of Crestor with Abbott’s already marketed fibrate TriCor, while the other

A protein anti-angiogenic agent is already approved by the FDA for clinical use. However, the new compounds developed by the university researchers are small molecules rather than proteins,

Boots Group and Alliance UniChem announced plans in October 2005 to create Alliance Boots, an international pharmacy-led healthcare group. Alliance investors will now receive 1.332 new Boots shares